secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q/C TECHNOLOGIES, INC. (QCLS)
CIK:        0001321834
Form:       8-K
Filed at:   2023-10-04T23:59:59+00:00
Accession:  0001493152-23-035667
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MyMD reports updated Phase 2 data for MYMD-1 in sarcopenia; TNF-α reduction statistically significant at 1050mg
--------------------------------------------------------------------------------

- Cohort 4 (1050mg) showed reduction in TNF-α over 28 days vs placebo (p=0.002 to 0.008).
- Phase 2 study met all primary PK and secondary safety/tolerability endpoints across multiple doses.
- FDA accepted IND for MYMD-1 in rheumatoid arthritis; Phase 2 trials planned.
- Company plans to present clinical safety report to FDA and seek guidance for Phase 3 trial in sarcopenia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1321834/000149315223035667/0001493152-23-035667-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1321834/000149315223035667/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-035667

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer